- Home
- HGTY vs CRMD Comparison
HGTY vs CRMD Comparison
Compare HGTY & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HGTY
- CRMD
- Stock Information
- Founded
- HGTY 1984
- CRMD 2006
- Country
- HGTY United States
- CRMD United States
- Employees
- HGTY N/A
- CRMD N/A
- Industry
- HGTY Specialty Insurers
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- HGTY Finance
- CRMD Health Care
- Exchange
- HGTY Nasdaq
- CRMD Nasdaq
- Market Cap
- HGTY 820.4M
- CRMD 877.5M
- IPO Year
- HGTY N/A
- CRMD 2010
- Fundamental
- Price
- HGTY $10.75
- CRMD $11.49
- Analyst Decision
- HGTY Hold
- CRMD Strong Buy
- Analyst Count
- HGTY 3
- CRMD 7
- Target Price
- HGTY $10.50
- CRMD $17.33
- AVG Volume (30 Days)
- HGTY 90.5K
- CRMD 2.3M
- Earning Date
- HGTY 08-04-2025
- CRMD 08-13-2025
- Dividend Yield
- HGTY N/A
- CRMD N/A
- EPS Growth
- HGTY 124.60
- CRMD N/A
- EPS
- HGTY 0.20
- CRMD 0.28
- Revenue
- HGTY $1,247,923,000.00
- CRMD $82,553,827.00
- Revenue This Year
- HGTY $15.41
- CRMD $278.96
- Revenue Next Year
- HGTY $15.88
- CRMD $45.85
- P/E Ratio
- HGTY $52.90
- CRMD $41.46
- Revenue Growth
- HGTY 18.45
- CRMD N/A
- 52 Week Low
- HGTY $8.03
- CRMD $3.61
- 52 Week High
- HGTY $12.35
- CRMD $17.43
- Technical
- Relative Strength Index (RSI)
- HGTY 78.22
- CRMD 44.95
- Support Level
- HGTY $10.08
- CRMD $10.70
- Resistance Level
- HGTY $10.15
- CRMD $11.92
- Average True Range (ATR)
- HGTY 0.20
- CRMD 0.44
- MACD
- HGTY 0.05
- CRMD 0.03
- Stochastic Oscillator
- HGTY 87.38
- CRMD 64.75
About HGTY Hagerty Inc.
Hagerty Inc is a provider of specialty automotive insurance. The company underwrites, sells, and services classic car and enthusiast vehicle insurance policies. Substantial revenue is derived from Commission and fees. Geographically it serves Europe, Canada, and the United States.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.